Abstract
The development of prophylactic and to lesser extent therapeutic vaccines for the prevention of disease associated with human cytomegalovirus (HCMV) infections has received considerable attention from biomedical researchers and pharmaceutical companies over the previous 15 years, even though attempts to produce such vaccines have been described in the literature for over 40 years. Studies of the natural history of congenital HCMV infection and infection in allograft recipients have suggested that prophylaxis of disease associated with HCMV infection could be possible, particularly in hosts at risk for more severe disease secondary to the lack of preexisting immunity. Provided a substantial understanding of immune response to HCMV together with several animal models that faithfully recapitulate aspects of human infection and immunity, investigators seem well positioned to design and test candidate vaccines. Yet more recent studies of the role of a maternal immunity in the natural history of congenital HCMV infection, including the recognition that reinfection of previously immune women by genetically distinct strains of HCMV occur in populations with a high seroprevalence, have raised several questions about the nature of protective immunity in maternal populations. This finding coupled with observations that have documented a significant incidence of damaging congenital infections in offspring of women with immunity to HCMV prior to conception has suggested that vaccine development based on conventional paradigms of adaptive immunity to viral infections may be of limited value in the prevention of damaging congenital HCMV infections. Perhaps a more achievable goal will be prophylactic vaccines to modify HCMV associated disease in allograft transplant recipients. Although recent descriptions of the results from vaccine trials have been heralded as evidence of an emerging success in the quest for a HCMV vaccine, careful analyses of these studies have also revealed that major hurdles remain to be addressed by current strategies.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Krech U, Konjajev Z, Jung M (1971) Congenital cytomegalovirus infection in siblings from consecutive pregnancies. Helv Paediatr Acta 26:355–362
Gold E, Nankervis GA (1976) Cytomegalovirus. In: Evans AS (ed) Viral infections of humans: epidemiology and control. Plenum, New York, pp 143–161
Pass RF et al (1981) Specific lymphocyte blastogenic responses in children with cytomegalovirus and herpes simplex virus infections acquired early in infancy. Infect Immun 34:166–170
Stagno S et al (1982) Maternal cytomegalovirus infection and perinatal transmission. Clin Obstet Gynecol 25:563–576
Marshall GS, Stout GG (2005) Cytomegalovirus seroprevalence among women of childbearing age during a 10-year period. Am J Perinatol 22:371–376
Kenneson A, Cannon MJ (2007) Review and meta-analysis of the epidemiology of congenital cytomegalovirus (CMV) infection. Rev Med Virol 17:253–276
Cannon MJ, Schmidt DS, Hyde TB (2010) Review of cytomegalovirus seroprevalence and demographic characteristics associated with infection. Rev Med Virol 20:202–213
Hyde TB, Schmidt DS, Cannon MJ (2010) Cytomegalovirus seroconversion rates and risk factors: implications for congenital CMV. Rev Med Virol 20:311–326
Hutto C et al (1985) Epidemiology of cytomegalovirus infections in young children: day care vs. home care. Pediatr Infect Dis 4:149–152
Stagno S et al (1986) Primary cytomegalovirus infection in pregnancy: incidence, transmission to fetus and clinical outcome. JAMA 256:1904–1908
Adler SP (1989) Cytomegalovirus and child day care. Evidence for an increased infection rate among day-care workers. N Engl J Med 321:1290–1296
Seo S, Cho Y, Park J (2009) Serologic screening of pregnant Korean women for primary human cytomegalovirus infection using IgG avidiyt test. Korean J Lab Med 29:557–562
Yamamoto AY et al (2012) Early high CMV seroprevalence in pregnant women from a population with a high rate of congenital infection. Epidemiol Infect 3:1–5
Saraswathy TS et al (2011) Seroprevalence of cytomegalovirus infection in pregnant women and associated role in obstetric complications: a preliminary study. Southeast Asian J Trop Med Public Health 42:320–322
Akinbami AA et al (2011) Seroprevalence of cytomegalovirus antibodies amongst normal pregnant women in Nigeria. Int J Womens Health 3:423–428
Hayes D, Danks M, Givas H, Jack I (1972) Cytomegalovirus in human milk. N Engl J Med 287:177
Lang DJ, Kummer JF (1975) Cytomegalovirus in semen: observations in selected populations. J Infect Dis 132:472–473
Reynolds DW et al (1973) Maternal cytomegalovirus excretion and perinatal infection. N Engl J Med 289:1–5
Alford CA, Stagno S, Pass RF (1980) Natural history of perinatal cytomegalovirus infection. In: Perinatal Infections. Excerpta Medica, Amsterdam, pp 125–147
Gold E, Nankervis GA (1982) Cytomegalovirus. In: Evans AS (ed) Viral infections of humans: epidemiology and control, 2nd edn. Plenum, New York, pp 167–186
Bate SL, Dollard SC, Cannon MJ (2010) Cytomegalovirus seroprevalence in the United States: the national health and nutrition examination surveys, 1988–2004. Clin Infect Dis 50:1439–1447
Schopfer K, Lauber E, Krech U (1978) Congenital cytomegalovirus infection in newborn infants of mothers infected before pregnancy. Arch Dis Child 53:536–539
Vial P et al (1985) Serological study of cytomegalovirus, herpes simplex and rubella virus, hepatitis B and Toxoplasma gondii in 2 populations of pregnant women in Santiago, Chile. Bol Oficina Sanit Panam 99:528–538
Mussi-Pinhata MM et al (2009) Birth prevalence and natural history of congenital cytomegalovirus infection in a highly seroimmune population. Clin Infect Dis 49:522–528
Dar L et al (2008) Congenital cytomegalovirus infection in a highly seropositive semi-urban population in India. Pediatr Infect Dis J 27:841–843
Stagno S et al (1980) Breast milk and the risk of cytomegalovirus infection. N Engl J Med 302:1073–1076
Hamprecht K et al (2001) Epidemiology of transmission of cytomegalovirus from mother to preterm infants by breastfeeding. Lancet 357:513–518
Sohn YM et al (1992) Congenital cytomegalovirus infection in Korean population with very high prevalence of maternal immunity. J Korean Med Sci 7:47–51
van der Sande MAB et al (2007) Risk factors for and clinical outcome of congenital cytomegalovirus infection in a peri-urban West-African birth cohort. PLoS One 2:e492
Boppana SB et al (2001) Intrauterine transmission of cytomegalovirus to infants of women with preconceptional immunity. N Engl J Med 344:1366–1371
Yamamoto AY et al (2010) Human cytomegalovirus reinfection is associated with intrauterine transmission in a highly cytomegalovirus-immune maternal population. Am J Obstet Gynecol 202(3):297e1–297e8
Chandler SH, Handsfield HH, McDougall JK (1987) Isolation of multiple strains of cytomegalovirus from women attending a clinic for sexually transmitted diseases. J Infect Dis 155:655–660
Ishibashi K et al (2007) Association of the outcome of renal transplantation with antibody response to cytomegalovirus strain-specific glycoprotein H epitopes. Clin Infect Dis 45:60–67
Ross SA et al (2010) Cytomegalovirus reinfections in healthy seroimmune women. J Infect Dis 201:386–389
Fowler KB, Stagno S, Pass RF (1993) Maternal age and congenital cytomegalovirus infection: screening of two diverse newborn populations, 1980–1990. J Infect Dis 168:552–556
Preece PM et al (1986) Congenital cytomegalovirus infection: predisposing maternal factors. J Epidemiol Community Health 40:205–209
Fowler KB, Stagno S, Pass RF (1991) Rates of congenital cytomegalovirus infection based on newborn screening in two populations over an eleven year interval. Pediatr Res 29:90A
Jordan MC et al (1973) Association of cervical cytomegaloviruses with venereal disease. N Engl J Med 288:932–934
Willmott FE (1975) Cytomegalovirus in female patients attending a VD clinic. Br J Vener Dis 51:278–280
Drew WL et al (1981) Prevalence of cytomegalovirus infection in homosexual men. J Infect Dis 143:188–192
Chandler SH et al (1985) The epidemiology of cytomegaloviral infection in women attending a sexually transmitted disease clinic. J Infect Dis 152:597–605
Sohn YM et al (1991) Cytomegalovirus infection in sexually active adolescents. J Infect Dis 163:460–463
Knox GE et al (1979) Comparative prevalence of subclinical cytomegalovirus and herpes simplex virus infections in the genital and urinary tracts of low income, urban females. J Infect Dis 140:419–422
Ahlfors K et al (1981) Secondary maternal cytomegalovirus infection causing symptomatic congenital infection. N Engl J Med 305:284
Stagno S et al (1982) Congenital cytomegalovirus infection: the relative importance of primary and recurrent maternal infection. N Engl J Med 306:945–949
Ahlfors K et al (1983) Congenital cytomegalovirus infection: on the relation between type and time of maternal infection and infant’s symptoms. Scand J Infect Dis 15:129–138
Stagno S et al (1983) Congenital and perinatal cytomegaloviral infections. Semin Perinatol 7:31–42
Fowler KB et al (1992) The outcome of congenital cytomegalovirus infection in relation to maternal antibody status. N Engl J Med 326:663–667
Demmler GJ (1990) Infectious Diseases Society of America and Centers for Disease Control: summary of a workshop on surveillance for congenital cytomegalovirus disease. Rev Infect Dis 13:315–329
Boppana SB et al (1999) Symptomatic congenital cytomegalovirus infection in infants born to mothers with preexisting immunity to cytomegalovirus. Pediatrics 104:55–60
Ahlfors K, Ivarsson SA, Harris S (1999) Report on a long-term study of maternal and congenital cytomegalovirus infection in Sweden. Review of prospective studies available in the literature. Scand J Infect Dis 31:443–457
Yamamoto AY et al (2011) Congenital cytomegalovirus infection as a cause of sensorineural hearing loss in a highly seropositive population. Pediatr Infect Dis J 30:1043–1046
Townsend CL et al (2013) Long-term outcomes of congenital cytomegalovirus infection in Sweden and the United Kingdom. Clin Infect Dis 56:1232–1239
Huang ES et al (1980) Molecular epidemiology of cytomegalovirus infections in women and their infants. N Engl J Med 303:958–962
Renzette N et al (2011) Extensive genome-wide variability of human cytomegalovirus in congenitally infected infants. PLoS Pathog 7:e1001344
Ross SA et al (2011) Mixed infection and strain diversity in congenital cytomegalovirus infection. J Infect Dis 204:1003–1007
Bale JF Jr et al (2001) Human cytomegalovirus a sequence and UL144 variability in strains from infected children. J Med Virol 65:90–96
Bale JF et al (1999) Cytomegalovirus transmission in child care homes. Arch Pediatr Adolesc Med 153:75–79
Chandler SH, McDougall JK (1986) Comparison of restriction site polymorphisms among clinical isolates and laboratory strains of human cytomegalovirus. J Gen Virol 67:2179–2192
Novak Z et al (2008) Cytomegalovirus strain diversity in seropositive women. J Clin Microbiol 46:882–886
Starr SE et al (1979) Impaired cellular immunity to cytomegalovirus in congenitally infected children and their mothers. J Infect Dis 140:500–505
Gehrz RC et al (1977) Specific cell-mediated immune defect in active cytomegalovirus infection of young children and their mothers. Lancet 2:844–847
Miles DJ et al (2008) CD4(+) T cell responses to cytomegalovirus in early life: a prospective birth cohort study. J Infect Dis 197:658–662
Tu W et al (2004) Persistent and selective deficiency of CD4+ T cell immunity to cytomegalovirus in immunocompetent young children. J Immunol 172:3260–3267
Marchant A et al (2003) Mature CD8(+) T lymphocyte response to viral infection during fetal life. J Clin Invest 111:1747–1755
Wang C et al (2011) Attribution of congenital cytomegalovirus infection to primary versus non-primary maternal infection. Clin Infect Dis 52:e11–13
Boppana SB, Britt WJ (1995) Antiviral antibody responses and intrauterine transmission after primary maternal cytomegalovirus infection. J Infect Dis 171:1115–1121
Britt WJ et al (1990) An immunodominant linear epitope on the major envelope glcoprotein complex (gB) of human cytomegalovirus, In: VIII international congress of virology, Berlin
Fouts AE et al (2012) Antibodies against the gH/gL/UL128/UL130/UL131 complex comprise the majority of the anti-cytomegalovirus (anti-CMV) neutralizing antibody response in CMV hyperimmune globulin. J Virol 86:7444–7447
Nigro G et al (2005) Passive immunization during pregnancy for congenital cytomegalovirus infection. N Engl J Med 353:1350–1362
Visentin S et al (2012) Early pregnancy cytomegalovirus infection in pregnancy: maternal hyperimmunoglobulin therapy improves outcomes among infants at 1 year of age. Clin Infect Dis 55:497–503
Maidji E et al (2006) Maternal antibodies enhance or prevent cytomegalovirus infection in the placenta by neonatal Fc receptor-mediated transcytosis. Am J Pathol 168:1210–1226
Pereira L et al (2003) Human cytomegalovirus transmission from the uterus to the placenta correlates with the presence of pathogenenic bacteria and maternal immunity. J Virol 77:13301–13314
Walker S et al (2007) Ex vivo monitoring of human cytomegalovirus-specific CD8+ T-cell responses using QuantiFeron-CMV. Transpl Infect Dis 9:165–170
Mattes FM et al (2008) Functional impairment of cytomegalovirus specific CD8 T cells predicts high-level replication after renal transplantation. Am J Transplant 8:990–999
Zanghellini F et al (1999) Asymptomatic primary cytomegalovirus infection: virologic and immunologic features. J Infect Dis 180:702–707
Hansen SG et al (2010) Evasion of CD8+ T cells is critical for superinfection by cytomegalovirus. Science 328:102–106
Sester M et al (2002) Sustained high frequencies of specific CD4 T cells restricted to a single persistent virus. J Virol 76:3748–3755
Gamadia LE et al (2003) Primary immune responses to human CMV: a critical role for IFN-gamma-producing CD4+ T cells in protection against CMV disease. Blood 101:2686–2692
Moss P, Khan N (2004) CD8(+) T-cell immunity to cytomegalovirus. Hum Immunol 65:456–464
Sylwester AW et al (2005) Broadly targeted human cytomegalovirus-specific CD4+ and CD8+ T cells dominate the memory compartments of exposed subjects. J Exp Med 202:673–685
Gyulai Z et al (2000) Cytotoxic T lymphocyte (CTL) responses to human cytomegalovirus pp 65, IE1-Exaon4, gB, pp150, and pp28 in healthy individuals: reevaluation of prevalence of IE1-specific CTSs. J Infect Dis 181:1537–1546
Lilleri D et al (2007) Development of human cytomegalovirus-specific T cell immunity during primary infection of pregnant women and its correlation with virus transmission to the fetus. J Infect Dis 195:1062–1070
Baldanti F et al (2006) Human cytomegalovirus UL131A, UL130, and UL128 genes are highly conserved among field isolates. Arch Virol 151:1225–1233
Lissauer D et al (2011) Cytomegalovirus seropositivity dramatically alters the maternal CD8+ T cell repertoire and leads to the accumulation of highly differentiated memory cells during human pregnancy. Hum Reprod 26:3355–3365
Li CR et al (1994) Recovery of HLA-restricted cytomegalovirus (CMV)-specific T-cell responses after allogeneic bone marrow transplant: correlation with CMV disease and effect of ganciclovir prophylaxis. Blood 83:1971–1979
Reusser P et al (1991) Cytotoxic T-lymphocyte response to cytomegalovirus after human allogeneic bone marrow transplantation: pattern of recovery and correlation with cytomegalovirus infection and disease. Blood 78:1373–1380
Walter EA et al (1995) Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N Engl J Med 333:1038–1044
Rosa L et al (2007) Longitudinal assessment of cytomegalovirus (CMV)-specific immune responses in liver transplant recipients at high risk for late CMV disease. J Infect Dis 195:633–644
Schooley RT et al (1983) Association of herpes virus infection with T-lymphocyte subset alterations, glomerulopathy, and opportunistic infections after renal transplantation. N Engl J Med 308:307–313
Sester M et al (2001) Levels of virus-specific CD4 T cells correlate with cytomegalovirus control and predict virus-induced disease after renal transplantation. Transplantation 71:1287–1294
Reusser P et al (1999) Cytomegalovirus (CMV)-specific T cell immunity after renal transplantation mediates protection from CMV disease by limiting the systemic virus load. J Infect Dis 180:247–253
Pourgheysari B et al (2009) Early reconstitution of effector memory CD4+ CMV-specific T cells protects against CMV reactivation following allogeneic SCT. Bone Marrow Transplant 43:853–861
Razonable RR (2008) Cytomegalovirus infection after liver transplantation: current concepts and challenges. World J Gastroenterol 14:4849–4860
Gallina A et al (1996) Human cytomegalovirus protein pp 65 lower matrix phosphoprotein harbours two transplantable nuclear localization signals. J Gen Virol 77:1151–1157
Riddell SR, Greenberg PD (1994) Therapeutic reconstruction of human viral immunity by adoptive transfer of cytotoxic T lymphocyte clones. Curr Top Microbiol Immunol 189:9–34
Riddell SR, Greenberg PD (2000) T-cell therapy of cytomegalovirus and human immunodeficiency virus infection. J Antimicrob Chemother 45:35–43
Komanduri KV et al (1998) Restoration of cytomegalovirus-specific CD4+ T-lymphocyte responses after ganciclovir and highly active antiretroviral therapy in individuals infected with HIV-1. Nat Med 4:953–956
Autran B et al (1997) Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease. Science 277:112–116
Bronke C et al (2005) Dynamics of cytomegalovirus (CMV)-specific T cells in HIV-1-infected individuals progressing to AIDS with CMV end-organ disease. J Infect Dis 191:873–880
Boppana SB et al (1995) Virus specific antibody responses to human cytomegalovirus (HCMV) in human immunodeficiency virus type 1-infected individuals with HCMV retinitis. J Infect Dis 171:182–185
Dylewski J, Chou S, Merigan TC (1983) Absence of detectable IgM antibody during cytomegalovirus disease in patients with AIDS [letter]. N Engl J Med 309:493
Rasmussen L et al (1994) Deficiency in antibody response to human cytomegalovirus glycoprotein gH in human immunodeficiency virus-infected patients at risk for cytomegalovirus retinitis. J Infect Dis 170:673–677
Arribas JR et al (1996) Cytomegalovirus encephalitis. Ann Intern Med 125:577–587
Evans PC et al (1999) Cytomegalovirus infection of bile duct epithelial cells, hepatic artery and portal venous endothelium in relation to chronic rejection of liver grafts. J Hepatol 31:913–920
Lautenschlager I et al (2006) Cytomegalovirus infection of the liver transplant: virological, histological, immunological, and clinical observations. Transpl Infect Dis 8:21–30
Myerson D, Hackman RC, Meyers JD (1984) Diagnosis of cytomegaloviral pneumonia by in situ hybridization. J Infect Dis 150:272–277
Myerson D et al (1984) Widespread presence of histologically occult cytomegalovirus. Hum Pathol 15:430–439
Schleiss MR (2006) Nonprimate models of congenital cytomegalovirus (CMV) infection: gaining insight into pathogenesis and prevention of disease in newborns. ILAR J 47:65–72
Britt WJ, Boppana S (2004) Human cytomegalviurs virion proteins. Hum Immunol 65:395–402
Jonjic S et al (2008) Immune evasion of natural killer cells by viruses. Curr Opin Immunol 20:30–38
Jonjic S et al (1990) Efficacious control of cytomegalovirus infection after long-term depletion of CD8+ T lymphocytes. J Virol 64:5457–5464
Jonjic S et al (1994) Antibodies are not essential for the resolution of primary cytomegalovirus infection but limit dissemination of recurrent virus. J Exp Med 179:1713–1717
Koszinowski UH, Reddehase MJ, Jonjic S (1991) The role of CD4 and CD8 T cells in viral infections. Curr Opin Immunol 3:471–475
Koszinowski UH et al (1987) Molecular analysis of herpesviral gene products recognized by protective cytolytic T lymphocytes. Immunol Lett 16:185–192
Krmpotic A et al (2003) Pathogenesis of murine cytomegalovirus infection. Microbes Infect 5:1263–1277
Polic B et al (1998) Hierarchical and redundant lymphocyte subset control precludes cytomegalovirus replication during latent infection. J Exp Med 188:1047–1054
Shanley JD (1991) Murine models of cytomegalovirus associated pneumonitis. Transplant Proc 23:S12–S16
Shanley JD, Biczak L, Formon SJ (1993) Acute murine cytomegalovirus infection induces lethal hepatitis. J Infect Dis 167:264–269
Koszinowski UH, Del Val M, Reddehase MJ (1990) Cellular and molecular basis of the protective immune response to cytomegalovirus infection. Curr Top Microbiol Immunol 154:189–220
Alcami A, Koszinowski UH (2000) Viral mechanisms of immune evasion. Immunol Today 21:447–455
Krmpotic A et al (2005) NK cell activation through the NKG2D ligand MULT-1 is selectively prevented by the glycoprotein encoded by mouse cytomegalovirus gene m145. J Exp Med 201:211–220
Zimmermann A et al (2005) A cytomegaloviral protein reveals a dual role for STAT2 in IFN-{gamma} signaling and antiviral responses. J Exp Med 201:1543–1553
LoPiccolo DM et al (2003) Effective inhibition of K(b)- and D(b)-restricted antigen presentation in primary macrophages by murine cytomegalovirus. J Virol 77:301–308
Lenac T et al (2006) The herpesviral Fc receptor fcr-1 down-regulates the NKG2D ligands MULT-1 and H60. J Exp Med 203:1843–1850
Krmpotic A et al (2001) The immunoevasive function encoded by the mouse cytomegalovirus gene m152 protects the virus against T cell control in vivo. J Exp Med 190:1285–1296
Krmpotic A et al (2002) MCMV glycoprotein gp40 confers virus resistance to CD8+ T cells and NK cells in vivo. Nat Immunol 3:529–535
Kavanagh DG et al (2001) The multiple immune-evasion genes of murine cytomegalovirus are not redundant: m4 and m152 inhibit antigen presentation in a complementary and cooperative fashion. J Exp Med 194:967–978
Hasan M et al (2005) Selective down-regulation of the NKG2D ligand H60 by mouse cytomegalovirus m155 glycoprotein. J Virol 79:2920–2930
Hengel H et al (1999) Cytomegaloviral control of MHC class I function in the mouse. Immunol Rev 168:167–176
Smith HR et al (2002) Recognition of a virus-encoded ligand by a natural killer cell activation receptor. Proc Natl Acad Sci U S A 99:8826–8831
Upton JW, Kaiser WJ, Mocarski ES (2010) Virus inhibition of RIP3-dependent necrosis. Cell Host Microbe 7:302–313
Lisnic VJ, Krmpotic A, Jonjic S (2010) Modulation of natural killer cell activity by viruses. Curr Opin Microbiol 14:530–539
Humphreys IR et al (2007) Cytomegalovirus exploits IL-10-mediated immune regulation in the salivary glands. J Exp Med 204:1217–1225
Reddehase MJ et al (1994) The conditions of primary infection define the load of latent viral genome in organs and the risk of recurrent cytomegalovirus disease. J Exp Med 179:185–193
Mathys S et al (2003) Dendritic cells under influence of mouse cytomegalovirus have a physiologic dual role: to initiate and to restrict T cell activation. J Infect Dis 187:988–999
Spencer JV et al (2002) Potent immunosuppressive activities of cytomegalovirus-encoded interleukin-10. J Virol 76:1285–1292
Chang WL, Barry PA (2009) Attenuation of innate immunity by cytomegalovirus IL-10 establishes a long-term deficit of adaptive antiviral immunity. Proc Natl Acad Sci U S A 107:22647–22652
Mandaric S et al (2012) IL-10 suppression of NK/DC crosstalk leads to poor priming of MCMV-specific CD4 T cells and prolonged MCMV persistence. PLoS Pathog 8:e1002846
Scalzo AA et al (2007) The interplay between host and viral factors in shaping the outcome of cytomegalovirus infection. Immunol Cell Biol 85:46–54
Jonjic S, Bubic I, Krmpotic A (2006) Innate immunity to cytomegaloviruses. In: Reddehase MJ (ed) Cytomegaloviruses: molecular biology and immunology. Caister, Norfolk, UK, pp 285–321
Klenovsek K et al (2007) Protection from CMV infection in immunodeficient hosts by adoptive transfer of memory B cells. Blood 110:3472–3479
Schlub TE et al (2011) Comparing the kinetics of NK cells, CD4, and CD8 T cells in murine cytomegalovirus infection. J Immunol 187:1385–1392
Walton SM et al (2008) The dynamics of mouse cytomegalovirus-specific CD4 T cell responses during acute and latent infection. J Immunol 181:1128–1134
Holtappels R et al (2008) CD8 T-cell-based immunotherapy of cytomegalovirus infection: “proof of concept” provided by the murine model. Med Microbiol Immunol 197:125–134
Cekinovic D et al (2008) Passive immunization reduces murine cytomegalovirus-induced brain pathology in newborn mice. J Virol 82:12172–12180
Pavic I et al (1993) Participation of endogenous tumour necrosis factor alpha in host resistance to cytomegalovirus infection. J Gen Virol 74(Pt 10):2215–2223
Scalzo AA, Yokoyama WM (2008) Cmv1 and natural killer cell responses to murine cytomegalovirus infection. Curr Top Microbiol Immunol 321:101–122
Vivier E et al (2011) Innate or adaptive immunity? The example of natural killer cells. Science 331:44–49
Rapp M et al (1993) In vivo protection studies with MCMV glycoproteins gB and gH expressed by vaccinia virus. In: Michelson S, Plotkin SA (eds) Multidisciplinary approach to understanding cytomegalovirus disease. Excerpta Medica, Amsterdam, pp 327–332
Reddehase MJ et al (1987) CD8-positive T lymphocytes specific for murine cytomegalovirus immediate-early antigens mediate protective immunity. J Virol 61:3102–3108
Del Val M et al (1991) Protection against lethal cytomegalovirus infection by a recombinant vaccine containing a single nonameric T-cell epitope. J Virol 65:3641–3646
Mohr CA et al (2010) A spread-deficient cytomegalovirus for assessment of first-target cells in vaccination. J Virol 84:7730–7742
Gonzalez Armas JC et al (1996) DNA immunization confers protection against murine cytomegalovirus infection. J Virol 70:7921–7928
Morello CS, Cranmer LD, Spector DH (2000) Suppression of murine cytomegalovirus (MCMV) replication with a DNA vaccine encoding MCMV M84 (a homolog of human cytomegalovirus pp 65). J Virol 74:3696–3708
Hakki M et al (2003) Immune reconstitution to cytomegalovirus after allogeneic hematopoietic stem cell transplantation: impact of host factors, drug therapy, and subclinical reactivation. Blood 102:3060–3067
Slavuljica I et al (2010) Recombinant mouse cytomegalovirus expressing a ligand for the NKG2D receptor is attenuated and has improved vaccine properties. J Clin Invest 120:4532–4545
Farrell HE, Shellam GR (1991) Protection against murine cytomegalovirus infection by passive transfer of neutralizing and non-neutralizing monoclonal antibodies. J Gen Virol 72:149–156
Farroway LN et al (2005) Transmission of two Australian strains of murine cytomegalovirus (MCMV) in enclosure populations of house mice (Mus domesticus). Epidemiol Infect 133:701–710
Gorman S et al (2006) Mixed infection with multiple strains of murine cytomegalovirus occurs following simultaneous or sequential infection of immunocompetent mice. J Gen Virol 87:1123–1132
Barry PA et al (2006) Nonhuman primate models of intrauterine cytomegalovirus infection. ILAR J 47:49–64
Assaf BT et al (2012) Patterns of acute rhesus cytomegalovirus (RhCMV) infection predict long-term RhCMV infection. J Virol 86:6354–6357
Lockridge KM et al (1999) Pathogenesis of experimental rhesus cytomegalovirus infection. J Virol 73:9576–9583
Kaur A et al (1996) Cytotoxic T-lymphocyte responses to cytomegalovirus in normal and simian immunodeficiency virus-infected rhesus macaques. J Virol 70:7725–7733
Yue Y, Zhou SS, Barry PA (2003) Antibody responses to rhesus cytomegalovirus glycoprotein B in naturally infected rhesus macaques. J Gen Virol 84:3371–3379
Kaur A et al (2002) Decreased frequency of cytomegalovirus (CMV)-specific CD4+ T lymphocytes in simian immunodeficiency virus-infected rhesus macaques: inverse relationship with CMV viremia. J Virol 76:3646–3658
Kaur A et al (2003) Direct relationship between suppression of virus-specific immunity and emergence of cytomegalovirus disease in simian AIDS. J Virol 77:5749–5758
Yue Y et al (2008) Evaluation of recombinant modified vaccinia Ankara virus-based rhesus cytomegalovirus vaccines in rhesus macaques. Med Microbiol Immunol 197:117–123
Yue Y et al (2007) Immunogenicity and protective efficacy of DNA vaccines expressing rhesus cytomegalovirus glycoprotein B, phosphoprotein 65-2, and viral interleukin-10 in rhesus macaques. J Virol 81:1095–1109
Wussow F et al (2013) A vaccine based on rhesus cytomegalovirus UL128 complex induces broadly neutralizing antibodies in rhesus macaques. J Virol 87:1322–1332
Hansen SG et al (2009) Effector memory T cell responses are associated with protection of rhesus monkeys from mucosal simian immunodeficiency virus challenge. Nat Med 15:293–299
Holtappels R et al (2001) Experimental preemptive immunotherapy of murine cytomegalovirus disease with CD8 T-cell lines specific for pp M83 and pM84, the two homologs of human cytomegalovirus tegument protein ppUL83 (pp65). J Virol 75:6584–6600
Podlech J et al (2000) Murine model of interstitial cytomegalovirus pneumona in syngenic bone marrow transplantation: persistence of protective pulmonary CD8-T-cell infiltrates after clearance of acute infection. J Virol 74:7496–7507
Holtappels R et al (2006) CD8 T-cell-based immunotherapy of cytomegalovirus disease in the mouse model of the immunocompromised bone marrow transplantation recipient. In: Reddehase MJ (ed) Cytomegaloviruses: molecular biology and immunology. Caister, Norfolk, UK, pp 383–419
Scalzo AA et al (1992) The effect of the Cmv-1 resistance gene, which is linked to the natural killer cell gene complex, is mediated by natural killer cells. J Immunol 149:581–589
Scalzo AA et al (1990) Cmv-1, a genetic locus that controls murine cytomegalovirus replication in the spleen. J Exp Med 171:1469–1483
Brown MG et al (1999) Localization on a physical map of the NKC-linked Cmv1 locus between Ly49b and the Prp gene cluster on mouse chromosome 6. J Immunol 163:1991–1999
Webb JR, Lee SH, Vidal SM (2002) Genetic control of innate immune responses against cytomegalovirus: MCMV meets its match. Genes Immun 3:250–262
Lee SH et al (2001) Susceptibility to mouse cytomegalovirus is associated with deletion of an activating natural killer cell receptor of the C-type lectin superfamily. Nat Genet 28:42–45
Depatie C et al (1999) Assessment of Cmv1 candidates by genetic mapping and in vivo antibody depletion of NK cell subsets. Int Immunol 11:1541–1551
Cheng TP et al (2008) Ly49h is necessary for genetic resistance to murine cytomegalovirus. Immunogenetics 60:565–573
Cooper MA, Yokoyama WM (2010) Memory-like responses of natural killer cells. Immunol Rev 235:297–305
Elliott JM, Yokoyama WM (2011) Unifying concepts of MHC-dependent natural killer cell education. Trends Immunol 32:364–372
Fodil-Cornu N et al (2008) Ly49h-deficient C57BL/6 mice: a new mouse cytomegalovirus-susceptible model remains resistant to unrelated pathogens controlled by the NK gene complex. J Immunol 181:6394–6405
Hadaya K et al (2008) Natural killer cell receptor repertoire and their ligands, and the risk of CMV infection after kidney transplantation. Am J Transplant 8:2674–2683
Bacon L et al (2004) Two human ULBP/RAET1 molecules with transmembrane regions are ligands for NKG2D. J Immunol 173:1078–1084
Bauer S et al (1999) Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science 285:727–729
Chalupny NJ et al (2003) ULBP4 is a novel ligand for human NKG2D. Biochem Biophys Res Commun 305:129–135
Eagle RA et al (2006) Regulation of NKG2D ligand gene expression. Hum Immunol 67:159–169
Eagle RA et al (2009) ULBP6/RAET1L is an additional human NKG2D ligand. Eur J Immunol 39:3207–3216
Rolle A et al (2003) Effects of human cytomegalovirus infection on ligands for the activating NKG2D receptor of NK cells: up-regulation of UL16-binding protein (ULBP)1 and ULBP2 is counteracted by the viral UL16 protein. J Immunol 171:902–908
Jonjic S et al (1989) Site-restricted persistent cytomegalovirus infection after selective long-term depletion of CD4+ T lymphocytes. J Exp Med 169:1199–1212
Lucin P et al (1992) Gamma interferon-dependent clearance of cytomegalovirus infection in salivary glands. J Virol 66:1977–1984
Holtappels R et al (1998) Control of murine cytomegalovirus in the lungs: relative but not absolute immunodominance of the immediate-early 1 nonapeptide during the antiviral cytolytic T-lymphocyte response in pulmonary infiltrates. J Virol 72:7201–7212
Reddehase MJ et al (1985) Interstitial murine cytomegalovirus pneumonia after irradiation: characterization of cells that limit viral replication during established infection of the lungs. J Virol 55:264–273
Kurz S et al (1997) Latency versus persistence or intermittent recurrences: evidence for a latent state of murine cytomegalovirus in the lungs. J Virol 71:2980–2987
Baroncelli S et al (1997) Cytomegalovirus and simian immunodeficiency virus coinfection: longitudinal study of antibody responses and disease progression. J Acquir Immune Defic Syndr Hum Retrovirol 15:5–15
Sequar G et al (2002) Experimental coinfection of rhesus macaques with rhesus cytomegalovirus and simian immunodeficiency virus: pathogenesis. J Virol 76:7661–7671
Reuter JD et al (2004) Systemic immune deficiency necessary for cytomegalovirus invasion of the mature brain. J Virol 78:1473–1487
Woolf NK, Jaquish DV, Koehrn FJ (2007) Transplacental murine cytomegalovirus infection in the brain of SCID mice. Virol J 4:26
Bia FJ et al (1983) Cytomegaloviral infections in the guinea pig: experimental models for human disease. Rev Infect Dis 5:177–195
Bia FJ, Miller SA, Davidson KH (1984) The guinea pig cytomegalovirus model of congenital human cytomegalovirus infection. Birth Defects 20:233–241
Griffith BP et al (1986) Inbred guinea pig model of intrauterine infection with cytomegalovirus. Am J Pathol 122:112–119
Borune N et al (2001) Preconception immunization with a cytomegalovirus (CMV) glycoprotein vaccine improves pregnancy outcome in a guniea pig model of congenital CMV infection. J Infect Dis 183:59–64
Schleiss MR (2007) Comparison of vaccine strategies against congenital CMV infection in the guinea pig model. J Clin Virol 41:224–230
Harrison CJ et al (1995) Reduced congenital cytomegalovirus (CMV) infection after maternal immunization with a guinea pig CMV glycoprotein before gestational primary CMV infection in the guinea pig model. J Infect Dis 172:1212–1220
Bratcher DF et al (1995) Effect of passive antibody on congenital cytomegalovirus infection in guinea pigs. J Infect Dis 172:944–950
Chatterjee A et al (2001) Modification of maternal and congenital cytomegalovirus infection by anti-glycoprotein b antibody transfer in guinea pigs. J Infect Dis 183:1547–1553
Woolf NK (1991) Guinea pig model of congenital CMV-induced hearing loss: a review. Transplant Proc 23:32–34
Park AH et al (2010) Development of cytomegalovirus-mediated sensorineural hearing loss in a guinea pig model. Arch Otolaryngol Head Neck Surg 136:48–53
Britt WJ, Cekinovic D, Jonjic S (2013) Murine model of neonatal cytomegalovirus infection. In: Reddehasse M (ed) Cytomegaloviruses. Cassister, London
Koontz T et al (2008) Altered development of the brain after focal herpesvirus infection of the central nervous system. J Exp Med 205:423–435
Kosmac K et al (2013) Glucocortiocoid treatment of MCMV infected newborn mice attenuates CNS inflammation and limits deficits in cerebellar development. PLoS Pathog 9:e1003200
Stagno S et al (1977) Congenital cytomegalovirus infection: occurrence in an immune population. N Engl J Med 296:1254–1258
Adler SP et al (1995) Immunity induced by primary human cytomegalovirus infection protects against secondary infection among women of childbearing age. J Infect Dis 171:26–32
Pass RF et al (2009) Vaccine prevention of maternal cytomegalovirus infection. N Engl J Med 360:1191–1199
Hansen SG et al (2011) Profound early control of highly pathogenic SIV by an effector memory T-cell vaccine. Nature 473:523–527
Wloch MK et al (2008) Safety and immunogenicity of a bivalent cytomegalovirus DNA vaccine in healthy adult subjects. J Infect Dis 197:1634–1642
Griffiths PD et al (2011) Cytomegalovirus glycoprotein-B vaccine with MF59 adjuvant in transplant recipients: a phase 2 randomised placebo-controlled trial. Lancet 377:1256–1263
Bernstein DI et al (2009) Randomized, double-blind, phase I trial of alphavirus replicon vaccine for cytomegalovirus in CMV seronegative adult volunteers. Vaccine 28:484–493
Heineman TC et al (2006) A phase 1 study of 4 live, recombinant human cytomegalovirus Towne/Toledo chimeric vaccines. J Infect Dis 193:1350–1360
La Rosa C et al (2012) Clinical evaluation of safety and immunogenicity of PADRE-cytomegalovirus (CMV) and tetanus-CMV fusion peptide vaccines with or without PF03512676 adjuvant. J Infect Dis 205:1294–1304
Snydman DR (1993) Review of the efficacy of cytomegalovirus immune globulin in the prophylaxis of CMV disease in renal transplant recipients. Transplant Proc 25:25–26
Yeager AS et al (1981) Prevention of transfusion-acquired cytomegalovirus infections in newborn infants. J Pediatr 98:281–287
Rubin R (2002) Clinical approach to infection in the compromised host. In: Rubin R, Young LS (eds) Infection in the organ transplant recipient. Kluwer Academic, New York, pp 573–679
Snydman DR et al (1987) Use of cytomegalovirus immune globulin to prevent cytomegalovirus disease in renal transplant recipients. N Engl J Med 317:1049–1054
Nigro G, Adler SP (2011) Cytomegalovirus infections during pregnancy. Curr Opin Obstet Gynecol 23:123–128
Hedlund M et al (2009) Human placenta expresses and secretes NKG2D ligands via exosomes that down-modulate the cognate receptor expression: evidence for immunosuppressive function. J Immunol 183:340–351
Iwasenko JM et al (2011) Human cytomegalovirus infection is detected frequently in stillbirths and is associated with fetal thrombotic vasculopathy. J Infect Dis 203:1526–1533
La Torre R et al (2006) Placental enlargement in women with primary maternal cytomegalovirus infection is associated with fetal and neonatal disease. Clin Infect Dis 43:994–1000
Pereira L, Maidji E (2008) Cytomegalovirus infection in the human placenta: maternal immunity and developmentally regulated receptors on trophoblasts converge. Curr Top Microbiol Immunol 325:383–395
Scott GM et al (2012) Cytomegalovirus infection during pregnancy with maternofetal transmission induces a proinflammatory cytokine bias in placenta and amniotic fluid. J Infect Dis 205:1305–1310
Cui X et al (2008) Cytomegalovirus vaccines fail to induce epithelial entry neutralzing antibodies comparable to natural infection. Vaccine 26:5760–5766
Gerna G et al (2008) Human cytomegalvirus serum neutralizing antibodies block virus infection of endothelial/epithelial cells but not fibroblasts, early during primary infection. J Gen Virol 89:853–865
Lilleri D et al (2012) Antibodies against neutralization epitopes of human cytomegalovirus gH/gL/pUL128-130-131 complex and virus spreading may correlate with virus control in vivo. J Clin Immunol 32:1324–1331
Jacobson MA et al (2009) A CMV DNA vaccine primes for memory immune responses to live-attenuated CMV (Towne strain). Vaccine 27:1540–1548
Boppana SB, Britt WJ (1996) Recognition of human cytomegalovirus gene products by HCMV-specific cytotoxic T cells. Virology 222:293–296
Borysiewicz LK et al (1988) Human cytomegalovirus-specific cytotoxic T cells: their precursor frequency and stage specificity. Eur J Immunol 18:269–275
Wills MR et al (1996) The human cytotoxic T lymphocyte (CTL) response to cytomegalovirus is dominated by structural protein pp 65: frequency, specificity and T-cell receptor usage of pp65-specific CTL. J Virol 70:7569–7579
Pass RF et al (1995) A phase I trial of BIOCINE CMV gB vaccine in seronegative adults. In: Fifth international cytomegalovirus conference, Stockholm, Sweden
Sabbaj S et al (2011) Glycoprotein B vaccine is capable of boosting both antibody and CD4 T-cell responses to cytomegalovirus in chronically infected women. J Infect Dis 203:1534–1541
Bubic I et al (2004) Gain of virulence caused by loss of a gene in murine cytomegalovirus. J Virol 78:7536–7544
Crnkovic-Mertens I et al (1998) Virus attenuation after deletion of the cytomegalovirus Fc receptor gene is not due to antibody control. J Virol 72:1377–1382
Chang WL et al (2009) Human cytomegalovirus suppresses type I interferon secretion by plasmacytoid dendritic cells through its interleukin 10 homolog. Virology 390:330–337
Logsdon NJ et al (2011) Design and analysis of rhesus cytomegalovirus IL-10 mutants as a model for novel vaccines against human cytomegalovirus. PLoS One 6:e28127
Jones BC et al (2002) Crystal structure of human cytomegalovirus IL-10 bound to soluble human IL-10R1. Proc Natl Acad Sci U S A 99:9404–9409
Stagno S et al (1982) Prevalence and importance of congenital cytomegalovirus infection in three different populations. J Pediatr 101:897–900
Adler SP et al (1996) Prevention of child-to-mother transmission of cytomegalovirus by changing behaviors: a randomized controlled trial. Pediatr Infect Dis J 15:240–246
Picone O et al (2009) A 2-year study on cytomegalovirus infection during pregnancy in a French hospital. BJOC 116:818–823
Paya CV et al (2004) Efficacy and safety of valganciclovir vs oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant 4:611–620
Kotton CN et al (2010) International consensus guidelines on the management of cytomegalovirus in solid organ transplantation. Transplantation 89:779–795
Asberg A et al (2009) Long-term outcomes of CMV disease treatment with valganciclovir versus IV ganciclovir in solid organ transplant recipients. Am J Transplant 9:1205–1213
Ljungman P et al (2008) Manamagement of CMV, HHV-6, HHV-7 and Kaposi-sarcoma associated herpesvirus (HHV-8) infections in patients with hematological malignancies and after SCT. Bone Marrow Transplant 42:227–240
Tomblyn M et al (2009) Guidelines for preventing infectious complications among hematopoietic cell transplant recipients: a global perspective. Biol Blood Marrow Transplant 15:1143–1238
Drew WL et al (1984) Multiple infections by cytomegalovirus in patients with acquired immune deficiency syndrome: documentation by Southern blot hybridization. J Infect Dis 150:952–953
Burkhardt C et al (2009) Glycoprotein N subtypes of human cytomegalovirus induce a strain-specific antibody response during natural infection. J Gen Virol 90:1951–1961
Dal Monte P et al (2001) The product of human cytomegalovirus UL73 is a new polymorphic structural glycoprotein (gpUL73). J Hum Virol 4:26–34
Gnann JW et al (1988) Inflammatory cells in transplanted kidneys are infected by human cytomegalovirus. Am J Pathol 132:239–248
Rasmussen L et al (2002) The genes encoding the gCIII complex of human cytomegalovirus exist in highly diverse combinations in clinical isolates. J Virol 76:10841–10848
Pass RF et al (2006) Congenital cytomegalovirus infection following first trimester maternal infection: symptoms at birth and outcome. J Clin Virol 35:216–220
Hodson EM et al (2005) Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients. Cochrane Database Syst Rev CD003774
Enders G et al (2011) Intrauterine transmission and clinical outcome of 248 pregnancies with primary cytomegalovirus infection in relation to gestational age. J Clin Virol 52:244–246
Andersen H et al (1979) A prosepctive study on the incidence and significance of congenital cytomegalovirus infection. Acta Paediatr Scand 68:329–336
Larke RBP et al (1980) Congenital cytomegalovirus infection in an urban Canadian community. J Infect Dis 142:647–653
Peckham CS et al (1983) Cytomegalovirus infection in pregnancy: preliminary findings from a prospective study. Lancet 1:1352–1355
Child SJ et al (2004) Evasion of cellular antiviral responses by human cytomegalovirus TRS1 and IRS1. J Virol 78:197–205
Brune W, Nevels M, Shenk T (2003) Murine cytomegalovirus m41 open reading frame encodes a Golgi-localized antiapoptotic progein. J Virol 77:11633–11643
Jurak I et al (2008) Murine cytomegalovirus m38.5 protein inhibits Bax-mediated cell death. J Virol 82:4812–4822
Cam M et al (2010) Cytomegaloviruses inhibit Bak- and Bax-mediated apoptosis with two separate viral proteins. Cell Death Differ 17:655–665
Skaletskaya A et al (2001) A cytomegalovirus-encoded inhibitor of apoptosis that suppresses caspase-8 activation. Proc Natl Acad Sci U S A 98:7829–7834
Brune W et al (2001) Secreted virus-encoded proteins reflect murinr cytomegalovirus productivity in organs. J Infect Dis 184:1320–1324
Lenac T et al (2008) Murine cytomegalovirus regulation of NKG2D ligands. Med Microbiol Immunol 197:159–166
Lodoen MB et al (2004) The cytomegalovirus m155 gene product subverts natural killer cell antiviral protection by disruption of H60-NKG2D interactions. J Exp Med 200:1075–1081
McCormick AL et al (2003) Differential function and expression of the viral inhibitor of caspase 8-induced apoptosis (vICA) and the viral mitochondria-localized inhibitor of apoptosis (vMIA) cell death suppressors conserved in primate and rodent cytomegaloviruses. Virology 316:221–233
Chalupny NJ et al (2006) Down-regulation of the NKG2D ligand MICA by the human cytomegalovirus glycoprotein UL142. Biochem Biophys Res Commun 346:175–181
Fruh K, Yang Y (1999) Antigen presentation by MHC class I and its regulation by interferon gamma. Curr Opin Immunol 11:76–81
Bubeck A et al (2002) The glycoprotein gp48 of murine cytomegalovirusL proteasome-dependent cytosolic dislocation and degradation. J Biol Chem 277:2216–2224
Vidal SM, Lanier LL (2006) NK cell recognition of moouse cytomegalovirus-infected cells. Curr Top Microbiol Immunol 298:183–206
Babic M et al (2010) Cytomegalovirus immunoevasion reveals the physiological role of “missing self” recognition in natural killer cell dependent virus control in vivo. J Exp Med 207:2663–2673
Tomazin R et al (1999) Cytomegalovirus US2 destroys two components of the MHC class II pathway, preventing recognition by CD+ T cells. Nat Med 5:1039–1043
Jackson SE, Mason GM, Wills MR (2011) Human cytomegalovirus immunity and immune evasion. Virus Res 157:151–160
Arora N et al (2010) Cytomegalovirus viruria and DNAemia in healthy seropositive women. J Infect Dis 202:1800–1803
Rivera LB et al (2002) Predictors of hearing loss in children with symptomatic congenital cytomegalovirus infection. Pediatrics 110:762–767
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2014 Springer Science+Business Media New York
About this protocol
Cite this protocol
Boppana, S.B., Britt, W.J. (2014). Recent Approaches and Strategies in the Generation of Antihuman Cytomegalovirus Vaccines. In: Yurochko, A., Miller, W. (eds) Human Cytomegaloviruses. Methods in Molecular Biology, vol 1119. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-62703-788-4_17
Download citation
DOI: https://doi.org/10.1007/978-1-62703-788-4_17
Published:
Publisher Name: Humana Press, Totowa, NJ
Print ISBN: 978-1-62703-787-7
Online ISBN: 978-1-62703-788-4
eBook Packages: Springer Protocols